Abstract

The attitudes toward the use of health technology assessment (HTA) in healthcare decision making vary widely between the United States and Europe and often even within Europe. Some countries use HTA extensively, others hardly at all. Some countries have independent HTA agencies; others adopt different institutional models. Some countries that conduct economic evaluations as part of HTA stress the use of quality-adjusted life-years (QALYs); others use other concepts of value.